Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
Study Details
Study Description
Brief Summary
Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the brain. This study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Treatment (fb-PMT) Daily subcutaneous injection of fb-PMT in three escalating cohorts to determine maximum tolerated dose, followed by treatment of up to 10 additional patients at maximum tolerated dose. |
Drug: fb-PMT
Daily dosing based on patient weight
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [15 months]
Determined by the number of Treatment-Emergent Adverse Events, including Dose-Limiting Toxicities per patient.
- Incidence of Dose Limiting Toxicities [Safety and Tolerability] [28 Days]
Number of participants with a dose-limiting toxicity during the first cycle (28 days) of treatment at their highest dose level administered.
Secondary Outcome Measures
- Establishment of Recommended Phase 2 Dose [28 Days]
Lesser of Optimum Biological Dose (determined by pharmacokinetic analysis) or Maximum Tolerated Dose (determined by Dose-Limiting Toxicities)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically proven intracranial glioblastoma, with first or second recurrence
-
On stable or decreasing dose of steroids, if taken prior to screening
-
Baseline MRI (with and without contrast) completed with 5 days of starting fb-PMT
-
Prior completion of and recovery from the effects of standard of care for glioblastoma management with surgery/biopsy and radiotherapy
-
Confirmation of true progressive disease for patients previously treated with interstitial brachytherapy or stereotactic radio surgery
-
Life expectancy of more than three months
-
Karnofsky Performance Status of ≥ 70
-
Hypertension must be well controlled (≤ 95th percentile) on stable doses of medication
-
Adequate bone marrow and organ function, confirmed by laboratory testing at screening
-
Patient or caregiver must be able to store drug under refrigerated conditions, prepare and administer daily subcutaneous injections on a set schedule, and record information in a daily treatment diary
-
Women of childbearing potential must agree to ongoing pregnancy testing and to use medically acceptable contraception for the duration of the study and for 2 months after their last dose of study drug
-
Males must agree to use medically acceptable contraception and refrain from donating sperm for the duration of the study and for 2 months after their last dose of study drug
Exclusion Criteria:
-
Significant medical illness that is uncontrolled, may obscure toxicity, may dangerously alter drug metabolism, or may compromise ability for study participation
-
History of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off all therapy for that disease for at least 3 months prior to first dose of study drug
-
Use of bevacizumab or any other experimental drug or therapy within 28 days of study treatment
-
Prior therapy with fb-PMT or related drugs
-
Currently pregnant or breastfeeding
-
Active infection or serious intercurrent medical illness
-
Surgery of any type within the preceding 28 days that has not fully healed
-
A serious or non-healing wound, ulcer, or bone fracture
-
A known bleeding diathesis or coagulopathy, or a history of bleeding diathesis within 28 days of study treatment
-
A known thrombophilic condition (i.e., protein S, protein C, or antithrombin III deficiency, Factor V Leiden, Factor II G20210A mutation, homocysteinemia or antiphospholipid antibody syndrome). Testing is not required in patients without thrombophilic history.
-
Evidence of new central nervous system hemorrhage on baseline MRI obtained within 14 days prior to study enrollment
-
Clinically significant cardiovascular event such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening.
-
New York Heart Association classification of heart disease greater than Class 2
-
QTc interval > 450 msec in males or > 470 msec in females at screening
-
Use of concomitant medications that prolong the QT/QTc interval or risk inducing Torsades de Pointes
-
Use of any concomitant Cytochrome P450 (CYP) inhibitors or CYP inducers within 14 days or five half-lives (whichever is longer) before starting study drug treatment
-
Abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months prior to study enrollment
-
A significant vascular disease (e.g., aortic aneurysm requiring surgical repair, deep venous or arterial thrombosis) within the last 6 months prior to study enrollment
-
History of stroke, myocardial infarction, transient ischemic attack (TIA), severe or unstable angina, peripheral vascular disease, or grade II or greater congestive heart failure within the past 6 months
-
History of Torsades de Pointes or risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Smilow Cancer Hospital | New Haven | Connecticut | United States | 06511 |
Sponsors and Collaborators
- NanoPharmaceuticals LLC
Investigators
- Principal Investigator: Anthony Omuro, MD, Yale University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NP-100-101